Literature DB >> 20375985

Visfatin is upregulated in type-2 diabetic rats and targets renal cells.

Young Sun Kang1, Hye Kyoung Song, Mi Hwa Lee, Gang Jee Ko, Jee Young Han, Sang Youb Han, Kum Hyun Han, Hyoung Kyu Kim, Dae Ryong Cha.   

Abstract

Visfatin (also known as pre-B cell colony-enhancing factor) is a newly discovered adipocytokine that is preferentially produced by visceral fat and regulated by cytokines promoting insulin resistance. Here we determined its renal synthesis and physiology in a genetic model of type 2 diabetes in rats. These rats had higher levels of visfatin synthesis in both glomeruli and tubulointerstitium compared to control rats. Plasma visfatin levels were significantly increased in the early stages of diabetic nephropathy and positively correlated with body weight, fasting plasma glucose, and microalbuminuria. Interestingly, visfatin synthesis was found to occur in podocytes and proximal tubular cells, as well as in adipocytes in vitro. Further, in both renal cells, visfatin synthesis was significantly increased by high glucose in the media but not by angiotensin II. Additionally, visfatin treatment induced rapid uptake of glucose and was associated with increased translocation of GLUT-1 to the cellular membrane of both renal cell types. Furthermore, visfatin induced tyrosine phosphorylation of the insulin receptor, activated downstream insulin signaling pathways such as Erk-1, Akt, and p38 MAPK, and markedly increased the levels of TGFbeta1, PAI-1, type I collagen, and MCP-1 in both renal cells. Thus, our results suggest that visfatin is produced by renal cells and has an important paracrine role in the pathogenesis of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375985     DOI: 10.1038/ki.2010.98

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  Adipokines protecting CKD.

Authors:  Satoshi Miyamoto; Kumar Sharma
Journal:  Nephrol Dial Transplant       Date:  2013-11       Impact factor: 5.992

Review 2.  The kidney in obesity.

Authors:  Josep Redon; Empar Lurbe
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

Review 3.  Obesity in kidney disease: A heavyweight opponent.

Authors:  Raphael Jose Ferreira Felizardo; Marina Burgos da Silva; Cristhiane Favero Aguiar; Niels Olsen Saraiva Câmara
Journal:  World J Nephrol       Date:  2014-08-06

4.  Irisin and Visfatin Predicts Severity of Diabetic Nephropathy.

Authors:  Ramalingam Mageswari; M G Sridhar; H Nandeesha; Sreejith Parameshwaran; K V Vinod
Journal:  Indian J Clin Biochem       Date:  2018-03-21

5.  Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy.

Authors:  Desirée Luis-Rodríguez; Alberto Martínez-Castelao; José Luis Górriz; Fernando De-Álvaro; Juan F Navarro-González
Journal:  World J Diabetes       Date:  2012-01-15

6.  Inhibition of pannexin-1 channel activity by adiponectin in podocytes: Role of acid ceramidase activation.

Authors:  Guangbi Li; Qinghua Zhang; Jinni Hong; Joseph K Ritter; Pin-Lan Li
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-01       Impact factor: 4.698

7.  Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.

Authors:  Susana Vallejo; Tania Romacho; Javier Angulo; Laura A Villalobos; Elena Cercas; Alejandra Leivas; Elena Bermejo; Raffaele Carraro; Carlos F Sánchez-Ferrer; Concepción Peiró
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

8.  The role of visfatin in diabetic nephropathy.

Authors:  Young Sun Kang; Dae Ryong Cha
Journal:  Chonnam Med J       Date:  2011-12-26

9.  Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2.

Authors:  Tingting Liu; Ziwei Miao; Jiusheng Jiang; Shuai Yuan; Wengang Fang; Bo Li; Yuhua Chen
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

10.  Albuminuria according to status of autoimmunity and insulin sensitivity among youth with type 1 and type 2 diabetes.

Authors:  Amy K Mottl; Abigail Lauer; Dana Dabelea; David M Maahs; Ralph B D'Agostino; Larry M Dolan; Lisa K Gilliam; Jean M Lawrence; Beatriz Rodriguez; Santica M Marcovina; Giuseppina Imperatore; Roopa Kanakatti Shankar; Maryam Afkarian; Kristi Reynolds; Angela D Liese; Michael Mauer; Elizabeth J Mayer-Davis
Journal:  Diabetes Care       Date:  2013-07-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.